QURE Healthcare, San Francisco, CA.
Baylor University Medical Center, Baylor Heart and Vascular Hospital, Baylor Heart and Vascular Institute, Texas A & M College of Medicine, Dallas, TX.
Curr Probl Cardiol. 2021 Sep;46(9):100851. doi: 10.1016/j.cpcardiol.2021.100851. Epub 2021 Apr 3.
Contrast-induced acute kidney injury (CI-AKI) occurs in up to 10% of cardiac catheterizations and coronary interventions, resulting in increased morbidity, mortality, and cost. One main reason for these complications and costs is under-recognition of CI-AKI risk and under-treatment of patients with impaired renal status. 157 interventional cardiologists each cared for three simulated patients with common conditions requiring intravascular contrast media in three typical settings: pre-procedurally, during the procedure, and post-procedure. We evaluated their ability to assess the risk of developing CI-AKI, make the diagnosis, and treat CI-AKI, including proper volume expansion and withholding nephrotoxic medications. Overall, the quality-of-care scores averaged 46.0% ± 10.5, varying between 18% to 78%. The diagnostic scores for accurately assessing risk of CI-AKI were low at 57.1% ± 21.2% and the accuracy of diagnosis pre-existing chronic kidney disease was 50.2%. Poor diagnostic accuracy led to poor treatment: proper volume expansion done in only 30.7% of cases, in-hospital repeat creatinine evaluation performed in 32.1%, and avoiding nephrotoxic medications occurred in 14.2%. While volume expansion was relatively similar across the three settings (P = 0.287), the cardiologists were less likely to discontinue nephrotoxic medications in pre-procedurally (9.7%) compared to the other settings (27.0%), and to order in-hospital creatinine testing in peri-procedurally (18.8%) compared to post-procedure (57.8%) (P < 0.05 for both). The overall care of patients at risk for contrast-induced acute kidney injury varied widely and showed room for improvement. Improving care for this condition will require greater awareness by cardiologists and better diagnostic tools to guide them.
造影剂相关急性肾损伤(CI-AKI)在心脏导管检查和冠状动脉介入治疗中发生率高达 10%,导致发病率、死亡率和成本增加。这些并发症和成本的一个主要原因是对 CI-AKI 风险的认识不足以及对肾功能受损患者的治疗不足。157 名介入心脏病学家每人负责照顾三个模拟患者,这些患者在三种典型情况下存在需要血管内造影剂的常见情况:术前、手术中和术后。我们评估了他们评估发生 CI-AKI 风险、做出诊断和治疗 CI-AKI 的能力,包括适当的容量扩张和停用肾毒性药物。总体而言,护理质量评分平均为 46.0%±10.5%,范围在 18%至 78%之间。准确评估 CI-AKI 风险的诊断评分较低,为 57.1%±21.2%,诊断预先存在的慢性肾脏病的准确性为 50.2%。较差的诊断准确性导致治疗不佳:仅在 30.7%的病例中进行适当的容量扩张,32.1%的病例在院内重复进行肌酐评估,仅 14.2%的病例避免使用肾毒性药物。虽然在三个环境中容量扩张相对相似(P=0.287),但与其他环境相比,心脏病学家在术前环境中更不可能停止使用肾毒性药物(9.7%),而在术中环境中更不可能在术后环境中(57.8%)进行院内肌酐检测(两者均 P<0.05)。有发生造影剂诱导的急性肾损伤风险的患者的整体护理差异很大,仍有改进的空间。改善对此类疾病的护理将需要心脏病学家提高认识并使用更好的诊断工具来指导他们。